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Poster Session II S319February 2009, 33 pts received CI CsA during their allogeneic
HSCT. Thirteen of these pts weighed$ 50 kg: 9 were males, the
median age was 16 years (11-18 years) and the mean weight was
66.3 kg (51.7 – 88 kg). Seven of 13 pts received dosa-
ges. 250 mg/day based on weight (6 of whom received 5 mg/kg/
day and 1 received  4 mg/kg/day (300 mg/day). Six pts received
dosages# 250 mg (5 of whom received 250 mg/day and 1 received
200 mg/day). After initial steady state, the median CsA level was
436 ng/ml (220-806, Mass-spectrometry). Toxicities that required
dose adjustment include: Hypertension (n5 5) Hyperbilirubinemia
(n5 3), increase in BUN/Cr (n5 1). 71% of pts$ 50 kg who re-
ceived weight based doses. 250 mg/day required a dose reduction
by the fifth day of therapy while none of the pts$ 50 kg receiving
doses# 250 mg/day needed dose adjustments (p5 0.02, Fisher’s
Exact Test). Two pts who received .250 mg/day dosage and did
not have a dose reduction in the first five days of therapy required
a dose reduction within 10 days of initiation of CsA due to toxicity.
No patients receiving the 250 mg maximum dose required an in-
crease above 250 mg in the first 5 days of therapy or dose adjust-
ment due to toxicity. This data supports the implementation of
a 250 mg/day maximum dosage of CI CsA for patients who
weigh$ 50 kg.Multivariable Logistic Regression Model for acute GVHD
Outcome
Variable OR 95% CI P
MTX vs. Siro 4.47 1.33-15 0.015
Age 0.894 0.95-1.04 NS
Female vs. Male 0.258 0.2-1.53 NS
MUD vs. MRD 0.842 0.36-3.49 NS
Acute Leukemia vs. Other 0.212 0.64-6.99 NS
Donor CMV positive 0.724 0.29-2.36 NS
Recipient CMV positive 0.008 1.5-14.4 0.008
PBSC vs. BM 0.159 0.71-7.85 NS
ATG 0.568 0.11-3.25 NS441
POLYOMA VIRUS IS THE PRINCIPAL CAUSE OF CYSTITIS FOLLOWING
ALEMTUZUMAB-BASED ALLOGENEIC STEM CELL TRANSPLANTATION
Khan, T.1, Richard, K.2, Broadwater, G.3, Hemphill, S.E.2, Lassiter, M.2,
Horwitz, M.E.4 1Duke University Medical Center, Durham, NC; 2Duke
University Medical Center, Durham, NC; 3Duke University Medical
Center, Durham, NC; 4Duke University School of Medicine, Durham,
NC
Polyoma virus reactivation and related cystitis in patients under-
going allogeneic hematopoietic stem cell transplant (alloHSCT) is
associated with significant morbidity. We conducted a retrospec-
tive review of 604 patients undergoing alloHSCT at Duke Univer-
sity Medical Center between Jan 1995 to Dec 2008. Polyoma virus
screening was performed on urine samples using electron micros-
copy (EM). EM screening was performed on 192 (32%) patients
with cystitis symptoms (dysuria, urgency, hesitancy, hemorrhage,
frequency). EM screened patients were evaluated for incidence
of polyoma infection, duration of symptoms, hemorrhagic cystitis,
and possible risk factors. Logistic regression modeling was used to
predict EM positivity in the 192 patients with symptomatic cysti-
tis. Pearson’s Chi-Square test was used to compare differences in
proportions. Of 192 patients screened, 96 (50%) tested positive
for polyoma virus. The median time to EM positivity was 1.38
months (n5 88). The median duration of symptoms in the EM
positive group was 1 month (range 15 days – 1 year), compared
to 15 days (range 15 days – 3 months) in the EM negative group.
Patients with symptomatic cystitis undergoing an alemtuzumab-
containing non-myeloablative transplantation (NMAT) had
a higher incidence of polyoma infection compared to standard
myeloablative alloHSCT (62% vs. 32%, Chi sq p\0.001). In
a subgroup analysis of NMAT patients, comparing regimen inten-
sity (Fludarabine/Cyclophosphamide 2 g/m2 vs. Fludarabine/Mel-
phalan 140 mg/m2 or Busulfan 260 mg/m2), no difference in the
incidence of polyoma infection was detected (67% vs 74%, Chi-
sq p5 0.497). This indicates that T-cell depletion has a greater
impact than regimen intensity on the development of polyoma in-
fection. Patients who received transplantation from a haploidenti-
cal donor were at greatest risk for developing polyoma infection
(Chi-sq p5 0.041). We found no difference in polyoma infection
rates based on the severity of graft vs. host disease. Ciprofloxacin
use did not attenuate the incidence of polyoma infection. A mul-
tivariate regression analysis identified alemtuzumab-containing
NMAT, haploidentical donor, and concurrent CMV infection as
risk factors for the development of polyoma infection. We con-
clude that polyoma virus was the predominant source of cystitis
in patient undergoing an alemtuzumab-containing NMAT. In
contrast to other published reports, regimen intensity is not
a major factor.442
SIROLIMUS COMPARED TO METHOTREXATE BASED IMMUNOSUPPRES-
SION FOR GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS IN AL-
LOGENEIC STEM CELL TRANSPLANTATION: A SINGLE INSTITUTION
EXPERIENCE
Kiel, P.J.1, Rosenbeck, L.L.1, Kalsekar, I.2, Baute, J.1, Abdelqader, S.1,
Sullivan, C.K.1, Schwartz, J.1, Srivastava, S.1, Abonour, R.1,
Robertson, M.J.1, Nelson, R.P.1, Fausel, C.A.1, Farag, S.S.1 1 IU Simon
Cancer Center, Indianapolis, IN; 2Butler University, Indianapolis, IN
Methotrexate (MTX) is a standard agent used in combination
with calcineurin inhibitors for GvHD prophylaxis in patients un-
dergoing an allogeneic hematopoeitic stem cell transplant
(HCT). We compared the incidence of acute GvHD following
allogeneic transplantation using the combination of sirolimus
(siro) and tacrolimus (tacro) to MTX plus either tacro or cyclo-
sporine.
Between January 1, 2005 and April 30, 2009, 106 consecutive
patients who received allogeneic bone marrow or peripheral blood
stem cell (PBSC) transplantation using a myeloablative regimen
for hematological malignancies were evaluated. Patients were
included if they were. 18 years old, and matched at least at HLA-
A, -B, and DRB1 by high-resolution typing. Patients receiving
reduced-intensity or cord blood transplantation were excluded.
The primary endpoint was the incidence and severity of acute
GvHD. Secondary endpoints included chronic GvHD, incidence
of venoocclusive disease (VOD), thrombotic microangiopathy
(TMA), interstitial pneumonitis (IP).
The median (range) age for the siro (n5 59) and MTX (n5 47)
groups were 44 (21-59) and 39 years (20-57), respectively. Of pa-
tients receiving MTX, 33 (70%) also received cyclosporine and 14
(30%) tacro. Thirty-four (57%) patients in the siro group and 19
(40%) in the MTX group received stem cells from matched unre-
lated donors (MUD). Forty-seven percent of MUD patients received
antithymocyte globulin (ATG) with siro/tacro.
The incidence of grade II-IV acute GvHD before day +100 was
18.6% in patients receiving siro/tacro, compared to 48.9% receiving
MTX (p5 0.001). The incidence of grade III-IV acute GVHD was
5% and 17% (p5 0.045) for the siro and MTX group, respectively.
The incidence of chronic GvHD was not significantly different be-
tween siro or MTX (32% vs. 38%, p5 0.5). Similarly, there was
no significant difference in the incidence of TMA or IP. However,
VOD occurred in 20% (attributable mortality in 8/12 patients)
who received siro compared to 4% in those receiving MTX (OR
0.103, 95% CI 0.10-1.093, p5 0.059).
This retrospective analysis demonstrated that the combination of
siro and tacro provided more effective acute GvHD prophylaxis
compared to MTX-based immunosupression. Siro was also associ-
ated with an increased incidence of VOD.TRANSPLANT NURSING: ADMINISTRATION
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ASSESSING PATIENT SATISFACTION IN AN OUTPATIENT APHERESIS SET-
TING
Merkel, D., Hirner, A., Gaillard, K., Torry, M., DeJarnette, S.,
Trieu, K., Lenz, K., Abhyankar, S. University of Kansas Hospital, Kansas
City, KS
Table 1. BMTOrientation Pathways
Type of RN
Length
of Orientation
Number
of Orientees
Track 1 Novice
(New RN or Nurse\2 years)
15 - 24 weeks 15
Track 2 Advanced Beginner
(Nurse with experience
in Med-Surg, Heme/Onc,
or Critical Care)
7 - 14 weeks 22
Track 3 Expert (Nurse with
BMTexperience)
4 - 6 weeks 4
S320 Poster Session IIPurpose: Processes and peer data are available to address patient
satisfaction in the inpatient setting, but evaluating satisfaction in
the outpatient setting has been historically over-looked. Our
outpatient apheresis unit has established a mechanism to assess
patient satisfaction and address the unobserved needs of our
patients.
Methods: We have developed patient satisfaction cards that are
given to patients upon completion of their procedure. Patients
have the opportunity to rate their care by answering the following
questions:
Was the procedure thoroughly explained by the apheresis staff?
Were your needs met during the procedure?
Were you treated in a courteous and professional manner?
Can you please rate the overall apheresis experience?
Ratings are on a scale from 1 to 5 with 1 being ‘very poor’ to 5 be-
ing ‘very good’. Patients are also given the opportunity to provide
comments regarding their procedure and the entire apheresis pro-
cess. The self-addressed scorecards are sent directly to our program’s
quality management coordinator for review and evaluation. Survey
participants are anonymous with names being optional.
Results:The goal of our hospital is to have a ‘good’ or ‘very good’
response on 90% of all patient satisfaction surveys. Our goal is to
exceed the needs of each patient and stay in-line with the hospital’s
desired goal. Tabulated results are reviewed with the apheresis
staff and are presented quarterly at our transplant program’s qual-
ity management meetings. Results and comments are posted
within the apheresis unit for continuous visualization of patient
satisfaction. Comments for improvement are entered into our
unit’s complaint log and are reviewed during our department
meetings.
Conclusion: Improved patient satisfaction is a high priority at our
institution. Patient satisfaction assessment is an excellent mechanism
for quality improvement activities. Evaluation of care, planning for
improvement and documentation of actions taken are a required
quality improvement activities for FACT accreditation for our
blood and marrow collection facility. Comment cards give our
patients an opportunity to express their appreciation for the care
provided by our staff. This provides an excellent affirmation of
a job well done.444
GROWTH OF A BMT UNIT IN TOUGH ECONOMIC TIMES: SUCCESS WITH A
STRUCTURED PROGRAM AND INNOVATIVE SOURCES OF FUNDING
Beaupierre, A.1, Thirlwell, S.1, Gillespie, M.1, Jones, G.M.2,
Reardon, M.B.1 1Moffitt Cancer Center, Tampa, FL; 2Moffitt Cancer
Center, Tampa, FL
In the past year, the Blood and Marrow Transplant (BMT) pro-
gram at our NCI-designated Cancer Center increased its inpatient
bed capacity by 80% and additional nursing staff was needed.
Given the challenges of the nursing shortage, the present economic
climate and the reality that nurses with BMT experience are un-
common, the Director of BMT and Critical Care Nursing, the
BMT Clinical Nurse Specialist (CNS) and the BMT Patient
Care Manager (PCM) formulated a plan to recruit and orient
nurses to meet our increased need and sought novel ways to fund
this initiative.
Safe and effective BMT nursing requires excellence in assessment,
critical thinking and care of acute and critical complications as well
knowledge in complex BMT treatment plans and skills in commu-
nication with patients, families and an interdisciplinary team.
BMT Nursing Leadership created a structured BMT Internship
Program to support successful recruitment and attainment of
BMT nursing proficiency. The program included didactic educa-
tion, an orientation manual and clinical orientation with a dedicated
preceptor. Clinical orientation was designed according to a BMT
Orientation Pathway, with three tracks individualized and varied
in length according to prior nursing and BMT experience, if any
(see Table 1).
Clinical orientation requires a significant financial investment
and the length of orientation became a concern. Nursing Leader-
ship partnered with Human Resources and the local unemployment
office to investigate opportunities for economic stimulus funds topartially fund the internship program. An ongoing partnership
with the local unemployment office will also create local sourcing
and networking opportunities for viable nursing candidates, as
well as the potential to receive funding through other designed
programs.
Over a 15-month period, 41 nurses were recruited for the BMT
Internship Program and were orientated according to the appropri-
ate track (see Table 1). The program had a 90% success rate with 37
nurses as new members of the BMT inpatient nursing team. Suc-
cesses and challenges of the BMT Internship Program have included
preceptor burnout and organizational issues as well as a change in
nursing culture. Future directions include preceptor support and
continued growth of the individual and collective BMT nursing
expertise.445
USE OF ‘‘RAPID-CYCLE’’ FAILURE MODE AND EFFECTS ANALYSIS (FMEA)
AND SIMULATION TO SAFELY TRANSITION HEMATOPOIETIC STEM CELL
(HSC) PROCESSING SERVICES
Halverson, T.1, Barnard, C.2, Collins, J.1, Duerst, R.1,3 1Children’s Me-
morial Hospital, Chicago, IL; 2NorthwesternMemorial Hospital, Chicago,
IL; 3Northwestern University, Chicago, IL
When Children’s Memorial Hospital (CMH) closed their he-
matopoietic stem cell (HSC) processing laboratory and con-
tracted with the affiliated Northwestern Memorial Hospital for
processing services, it required substantial practice changes and
introduced potential safety risks. The 3-month transition timeline
required the transplant program to make optimal use of time and
resources. ‘‘Rapid-cycle’’ FMEA followed by simulation was used
to evaluate, refine and test the process changes required for this
transition.
Failure mode and effects analysis (FMEA) is a systems-oriented,
prospective approach to process improvement and risk reduction.
FMEA identifies potential process fail-points, assesses their level of
risk, and helps prioritize response with the goal of reducing error oc-
currence and/or mitigating harm. Traditional FMEA is effective but
time-intensive. The ‘‘rapid-cycle’’ adaptation focuses on efficient use
of FMEA meeting time and reduces clinician stakeholder’s involve-
ment to two meetings (see table 1).
To keep the scope manageable, two ‘‘rapid-cycle’’ FMEAs were
conducted. An inter-facility FMEA focused on information and
cell hand-off, and included representation from the hospital, pro-
cessing facility, and courier company. A second, intra-facility
FMEA focused on process changes occurring within the clinical pro-
gram.
The joint FMEA sessions identified 51 potential failure modes.
Failure modes were scored for severity, frequency and detectability;
those identified as high or moderate severity were corrected. The
two items identified as highest risk were (1) incomplete or inaccurate
chain of custody documentation and (2) incomplete information
hand-off between the two institutions. These fail-points were part
of a new process step that required hand-off of cells from CMH to
the outside processing facility via courier. The process was revised
using recommendations developed during the FMEAs, then tested
before the move using simulation.
Sequential use of ‘‘rapid-cycle’’ FMEA followed by simulation
allowed the stem cell transplant program to ‘design out’ potential
